Meeting the challenges of PET-based molecular imaging in cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Vogelstein B. Genetic testings for cancer: the surgeon's critical role. Familial colon cancer. J. Am. Coll. Surg. 188(1), 74–79 (1999).
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012).
   PubMed Web of Science ®Google Scholar
• Chang MC, Malowany JI, Mazurkiewicz J, Wood M. ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases. Mod. Pathol. 25(5), 683–688 (2012).
   PubMed Web of Science ®Google Scholar
• Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Sem. Oncol. 27(5 Suppl. 9), 13–19 (2000).
   PubMed Web of Science ®Google Scholar
• Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 70(10), 3935–3944 (2010).
   PubMed Web of Science ®Google Scholar
• Conti PS, McEwan AJ, Pomper MG. Molecular imaging: the future of modern medicine. J. Nucl. Med. 49(6), 16N–20N (2008).
   Web of Science ®Google Scholar
• Pomper MG. Translational molecular imaging for cancer. Cancer Imaging S16–S26 (2005).
   Google Scholar
• Bensinger S, Christofk H. New aspects of the Warburg effect in cancer cell biology. Semin. Cell Dev. Biol. 23(4), 352–361 (2012).
   PubMed Web of Science ®Google Scholar
• Drzezga A, Souvatzoglou M, Eiber M et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J. Nucl. Med. 53(6), 845–855 (2012).
   PubMed Web of Science ®Google Scholar
• Ribom D, Engler H, Blomquist E, Smits A. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur. J. Nucl. Med. Mol. Imaging 29(5), 632–640 (2002).
   PubMed Web of Science ®Google Scholar
• McConathy J, Yu W, Jarkas N, Seo W, Schuster DM, Goodman MM. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med. Res. Rev. 32(4), 868–905 (2012).
   PubMed Web of Science ®Google Scholar
• Schuster DM, Nye JA, Nieh PT et al. Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma. Mol. Imaging Biol. 11(6), 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Grassi I, Nanni C, Allegri V et al. The clinical use of PET with (11)C-acetate. Am. J. Nucl. Med. Mol. Imaging 2(1), 33–47 (2012).
   PubMedGoogle Scholar
• Albrecht S, Buchegger F, Soloviev D et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging 34(2), 185–196 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs AH, Thomas A, Kracht LW et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J. Nucl. Med. 46(12), 1948–1958 (2005).
   PubMed Web of Science ®Google Scholar
• Linden HM, Kurland BF, Peterson LM et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin. Cancer Res. 17(14), 4799–4805 (2011).
   PubMed Web of Science ®Google Scholar
• Beattie BJ, Smith-Jones PM, Jhanwar YS et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 51(2), 183–192 (2010).
   PubMed Web of Science ®Google Scholar
• Larson SM, Morris M, Gunther I et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45(3), 366–373 (2004).
   PubMed Web of Science ®Google Scholar
• Bander NH, Trabulsi EJ, Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170(5), 1717–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Perik PJ, Lub-De Hooge MN, Gietema JA et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 24(15), 2276–2282 (2006).
   PubMed Web of Science ®Google Scholar
• Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantification of receptor-ligand binding with [(1)(8)F]fluciclatide in metastatic breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 38(12), 2186–2197 (2011).
   PubMed Web of Science ®Google Scholar
• Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol. Biol. 248, 209–225 (2004).
   PubMedGoogle Scholar
• De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. Apoptosis imaging to monitor cancer therapy: the road to fast treatment evaluation? Curr. Pharm. Biotechnol. 13(4), 571–583 (2012).
   PubMed Web of Science ®Google Scholar
• Jacobson O, Weiss ID, Szajek LP et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 1, 251–262 (2011).
   PubMed Web of Science ®Google Scholar
• Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83(2), 245–253 (1998).
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Schlag P et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J. Nucl. Med. 39(7), 1197–1202 (1998).
   PubMed Web of Science ®Google Scholar
• Ginos JZ, Cooper AJ, Dhawan V et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28(12), 1844–1852 (1987).
   PubMed Web of Science ®Google Scholar
• De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J. Nucl. Med. 52(6), 986–993 (2011).
   PubMed Web of Science ®Google Scholar
• Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg. Med. Chem. 17(4), 1486–1493 (2009).
   PubMed Web of Science ®Google Scholar
• Cho SY, Gage KL, Mease RC et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 53(12), 1883–1891 (2012).
   PubMed Web of Science ®Google Scholar
• Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 40(6), 819–823 (2013).
   PubMed Web of Science ®Google Scholar
• Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33(10), 1115–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J. Nucl. Med. 48(8), 1245–1250 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas CT, Bradshaw PT, Pollock BH et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J. Clin. Oncol. 21(9), 1715–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Nagda SN, Mohideen N, Lo SS et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(3), 834–840. (2007).
   PubMed Web of Science ®Google Scholar
• Troyer JK, Feng Q, Beckett ML, Wright GLJr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol. 1(1), 29–37 (1995).
   PubMedGoogle Scholar
• Shan L. Gallium-68-dotamaleimide-Cys2-annexin A5. In: Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US), Bethesda, MD, USA, 2004-2013 (2011).
   Google Scholar
• Administration FaHHSD. Current good manufacturing practice for positron emission tomography drugs. Fed. Regist. 74(236), 65409–65436 (2009).
   PubMedGoogle Scholar